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Abstract: The use of herbomineral formulations in the healthcare sector has increased due to their high safety and better 
therapeutic action. A new proprietary herbomineral formulation was formulated with a mixture of the herbal root extract of 
ashwagandha and three minerals viz. zinc chloride, magnesium gluconate, and sodium selenate. The aim of the study was to 
evaluate the immunomodulatory potential of Biofield Energy Healing (The Trivedi Effect®) on the formulation when applied to 
splenocyte cells isolated from mice spleen. The formulation was divided into two parts; one was the control without any 
Biofield Energy Treatment, while the other part was defined as the Biofield Energy Treated sample, which received Biofield 
Energy Healing Treatment remotely by seven renowned Biofield Energy Healers. The test formulation was evaluated to find 
the expression of pro-inflammatory cytokines such as TNF-α, MIP-1α, and IL-1β along with non-cytotoxic concentrations by 
MTT assay. The splenocytes were given the Biofield Energy Treated and untreated sample at concentrations range 
(0.00001053 to 10.53 µg/mL) for 48 hours and was reported with safe concentration up to 1.053 µg/mL with percentage 
viability range from 76.7% to 109.2% in both samples. Biofield Energy Healing significantly enhanced the cell viability as 
compared with the untreated formulation. The expression of TNF-α was significantly inhibited in the Biofield Treated 
formulation at 0.01053, 0.1053, and 1.053 µg/mL by 1.77%, 1.93%, and 3.55%, respectively compared with the untreated 
formulation. The rest of the tested concentrations of the Biofield Treated formulation showed an increase in TNF-α expression 
at 0.00001053, 0.0001053, and 0.001053 µg/mL by 7.26%, 8.50%, and 8.50%, respectively compared to the vehicle control 
group. Similarly, the MIP-1α expression was inhibited by the Biofield Energy Treated formulation and showed 
immunosuppression activity at 0.01053 µg/mL by 18.47% (p≤0.001) compared to the untreated formulation. MIP-1α 
expression was reported as 628.94 ± 13.0 pg/mL in the untreated formulation, while it decreased to 512.74 ± 1.9 pg/mL in the 
Biofield Treated formulation at 0.01053 µg/mL. In addition, the IL-1β secretion was also significantly inhibited by the Biofield 
Treated formulation at concentrations 0.001053, 0.01053, 0.1053, and 1.053 µg/mL by 72.02%, 50.16%, 30.68%, and 22.11%, 
respectively as compared with the untreated formulation. Overall, The Trivedi Effect® significantly down-regulated the pro-
inflammatory cytokines and potentiated the immunosuppressive effect of the treated formulation, which can be better utilized 
in organ transplants, anti-aging, stress management, autoimmune disorders, and inflammatory disorders, etc. to modulate the 
immune system by improving overall health.  
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1. Introduction 
The healing properties of plant extracts have been 
recognized and utilized worldwide since ancient times. Plant 
products and their extracts are used in both allopathic health 
care as well as complementary and alternative health care in 
order to improve overall health and the immune system [1, 
2]. However, much attention has been focused on discovering 
herbal products with immunomodulatory activity along with 
low toxicity and better bioavailability [3]. Many scientific 
studies have identified the immunomodulatory properties of 
medicinal plants, which can be further potentiated with the 
addition of some minerals that regulate the immune cells. 
These types of formulations are commonly defined as 
herbomineral formulations and are the major target for 
pharmaceutical companies as phytopharmaceutical products 
or as dietary supplements. Based on the literature, a new 
proprietary herbomineral formulation was formulated with a 
combination of the herb ashwagandha root extract and three 
minerals viz. zinc, magnesium, and selenium. All the 
ingredients of the formulation in this present study possess 
important activities such as immune modulating properties, 
anti-inflammatory, antioxidant, anti-infective, and anti-viral 
[4-7]. Withania somnifera (ashwagandha) biological activity 
is mainly reported due to the presence of withanolides, and it 
is used as complementary medicine in alternative therapies 
[8, 9]. Apart from its common attributes such as antibacterial, 
immunomodulatory and antitumor effects, many clinical and 
preclinical data have been available with respect to its 
immunomodulatory impact [4, 10]. The importance of 
minerals such as selenium, zinc, and magnesium is to 
modulate the immune system because their synergistic 
impact has been well-defined [5]. 
Scientific research has documented that in the presence of 
minerals, herbal medicines have been found to exhibit a high 
level of phagocytic index and improved antibody titre [11]. 
These formulations can be used for better therapeutic effect in 
immune compromised patients affected with cardiovascular 
diseases, age and stress related diseases, cancer, and 
autoimmune disorders. Along with herbomineral formulations, 
the Biofield Energy Healers in this study have used energy 
medicine (Biofield Energy Healing Treatment) as a 
complementary and alternative approach to study the impact of 
Biofield Treatment on the herbomineral formulation for its 
immunomodulatory potential with respect to the pro-
inflammatory cytokines in splenocyte cells isolated from mice.  
In recent years, several scientific reports along with 
clinical trials have shown the useful effects of Biofield 
Energy Treatment, which has shown enhanced immune 
function in cases of cervical cancer patients with therapeutic 
touch [12], massage therapy [13], etc. Complementary and 
Alternative Medicine (CAM) are recognized therapies by The 
National Center for Complementary and Integrative Health 
(NCCIH). Human Biofield Energy has subtle energy that has 
the capacity to work in an effective manner [14]. Reports 
show that Complementary and Alternative Medicine (CAM) 
therapies have been practiced worldwide with reported 
clinical benefits in different health disease profiles [15]. This 
energy can be harnessed and transmitted by individuals into 
living and non-living things via the process of Biofield 
Energy Healing. Biofield Energy Treatment (The Trivedi 
Effect®) has been extensively studied with significant 
outcomes in many scientific fields such as cancer research 
[16, 17], altered antimicrobial sensitivity of pathogenic 
microbes in microbiology [18-21], genetics [22, 23], altered 
physical and chemical properties of pharmaceutical 
compounds [24-27], improved overall growth and yield of 
plants in agricultural science [28-31], and in changing the 
structure of the atom in relation to various metals, ceramics, 
polymers and chemicals in materials science [32-35]. 
The authors of this study want to evaluate the impact of 
Biofield Energy Treatment (The Trivedi Effect®) on the given 
herbomineral formulation, which might improve the 
immunomodulatory function in in vitro cellular models on 
mice splenocyte cells. 
2. Materials and Methods 
2.1. Chemicals and Reagents 
Lipopolysaccharide (LPS), 3-(4, 5-diamethyl-2-thiazolyl) 
2, 5 diphenyl-2 H-tetrazolium) (MTT), Roswell Park 
Memorial Institute (RPMI-1640), L-glutamine, penicillin, 
streptomycin, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES), 2- mercaptoethanol, concanavalin A (Con-A), 
rapamycin, NaHCO3, and EDTA were purchased from Sigma 
Chemical Corp. (St. Louis, MO), a subsidiary of Sigma-
Aldrich Corporation. ELISA (enzyme-link immunosorbent 
assay) assay kits for all cytokines tumor necrosis factor alpha 
(TNF-α), macrophage inflammatory protein-1α (MIP-1α), 
and interleukin-1 beta (IL-1β) were purchased from R&D 
Systems, USA. Fetal bovine serum (FBS) was purchased 
from GIBCO, USA. All other chemicals used were of 
analytical grade available in India. Ashwagandha (Withania 
somnifera) root extract powder (≥ 5% of total withanolides) 
was procured from Sanat Products Ltd., India. Zinc chloride 
and magnesium (II) gluconate hydrate were procured from 
Tokyo Chemical Industry Co., Ltd. (TCI), Japan. Sodium 
selenate was procured from Alfa Aesar, USA.  
2.2. Test Formulation and Reference Standard 
The test formulation contained a combination of four 
ingredients: ashwagandha root powder extract, zinc chloride, 
sodium selenate, and magnesium gluconate. LPS was used as 
an inflammatory stimulant, while Con-A and rapamycin were 
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used as a reference standard (positive control) for 
immunostimulatory and immunosuppressive action 
respectively in splenocytes assay.  
2.3. Experimental Animal 
C57BL/6 male mice (8 weeks old, 22 gm body weight) 
were purchased from Vivo Bio Tech Ltd., Hyderabad, India 
and acclimatized for one week prior to the experiments. 
Laboratory rodent diet and drinking tap water were provided 
ad libitum and were maintained under controlled conditions 
with a temperature of 22 ± 3°C, humidity of 30% to 70% and 
a 12-hour light/12-hour dark cycle. All the procedures were 
in strict accordance with the Guide for the Care and Use of 
Laboratory Animals published by the US National Institutes 
of Health (NIH). The approval of the Institutional Animal 
Ethics Committee (IAEC) was obtained prior to carrying out 
the animal experiment. 
2.4. Biofield Energy Healing Strategies 
One part of the test formulation did not receive any sort of 
treatment and was defined as the control group, while 
Biofield Energy Treatment was given to the herbomineral 
formulation defined as the treated group. The Biofield 
Energy Treatment was administered for 5 minutes by the 
seven Biofield Energy Healers (The Trivedi Effect®), six of 
which were remotely located in the U. S. A. and one of 
which was remotely located in Canada, while the test 
formulation was located in Dabur Research Foundation near 
New Delhi in Ghaziabad, India, under standard laboratory 
conditions. This treatment was provided through the Biofield 
Energy Healers’ unique Energy Transmission process (The 
Trivedi Effect®) remotely to the test formulation. Further, the 
control group was treated by a sham healer for comparative 
purposes. The sham healer does not have any knowledge 
about the Biofield Energy Treatment. After that, the Biofield 
Energy Treated and untreated samples were kept in similar 
sealed conditions and used for the in vitro study on 
splenocyte cells for cytokines estimation.  
2.5. Experimental Design 
The experimental study was divided into 7 groups. Group 1 
comprised of the splenocyte cells without LPS and was 
denoted as the negative control. Group 2 served as a 
stimulant group that includes cells with LPS. Group 3 
included the splenocyte cells with LPS along with vehicle 
(0.005% DMSO) denoted as the vehicle control. Groups 4 
and 5 were defined as the positive control, which includes 
cells with Con-A (0.5 μg/mL) and rapamycin (1 nm and 10 
nm), respectively. Groups 6 and 7 were denoted as the test 
item groups that included splenocyte cells with LPS along 
with untreated and Biofield Treated formulations, 
respectively, at concentration 0.00001053 to 10.53 µg/mL. 
After 48 hours of incubation, supernatants were analyzed for 
the secreted levels of TNF-α, MIP-1α, and IL-1β using 
ELISA as per the manufacturer’s instructions. Concentrations 
were determined in triplicate wells of each sample. 
2.6. Isolation of Murine Splenocytes 
C57BL/6 male mice were sacrificed and the spleens were 
aseptically removed and grounded by passing through a 
sterile plastic strainer under aseptic conditions. After the cells 
were centrifuged twice at 1000 g for 5 minutes, erythrocytes 
were lysed by a lysis buffer (0.15 M NH4Cl, 0.01 M 
NaHCO3, and 0.1 mM EDTA, pH 7.4) and then the cell 
pellets were washed twice with the RPMI-1640 medium. 
Further, the cells were resuspended in the complete RPMI-
1640 medium (RPMI 1640 medium plus 10% fetal bovine 
serum, 2 mM glutamine, 100 IU/mL of penicillin and 
streptomycin, 15 mM HEPES and 50 mM 2-
mercaptoethanol). The cell counts were performed using a 
hemocytometer and cell viability was determined using the 
trypan-blue dye exclusion technique with the results showing 
≥95% of viable cells. The cells were cultured in 96-well 
tissue culture plates with 0.2 x 106 cells per well. They were 
incubated at 37°C in a humidified atmosphere of 5% CO2 for 
the indicated period [36]. 
2.7. Cell Culture and Test Formulation Treatment 
Splenocyte (0.2 x 106 cells per well) cells were grown in 
96-well culture plates using a RPMI-1640 medium 
supplemented with 10% FBS, 100 units/mL of penicillin, and 
100 µg/mL of streptomycin. LPS (50 ng/mL) induced 
splenocyte cells cultures were grown for 48 hours at 37oC in 
a humidified CO2 incubator (5% CO2). The effect of 
cytotoxicity of the formulation was tested by treating cells 
with different concentrations of the test formulation in 
RPMI-1640 medium. The various concentrations of the test 
formulation were used i.e. 0.00001053 µg/mL to 10.53 
µg/mL in the presence of inflammatory stimulus (LPS) for 
cell viability assay. The respective vehicle controls (DMSO) 
were kept in the assay for comparison. 
2.8. Cytotoxicity by MTT Assay 
The effect of the Biofield Treated and untreated 
formulations at the concentration range of 0.00001053 
µg/mL to 10.53 µg/mL were tested for cell viability using 3-
(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT) assay. The number of viable cells was determined by 
the ability of mitochondria to convert MTT to formazan dye. 
Splenocyte cells were cultured overnight in 96-well plates, at 
a density of 0.2 x 106 cells per well. After treatment with the 
test formulation and incubation period, the medium was 
removed. 20 µL of 5 mg/mL MTT was then added to each 
well and incubated for 3 hours further at 37ºC in a humidified 
5% CO2 atmosphere. The cells were centrifuged and 
supernatants were removed. The cell pellet in each well was 
resuspended in 150 µL of DMSO to dissolve formazan 
crystals. The optical density of each well was read at 540 nm 
using BioTek Reader (SIAFRT/Synergy HT multimode 
reader, US).  
The effect of the formulation on cell viability of splenocyte 
cells was determined as per equation (1):  
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%	Cell	viability  100 %	cytotoxicity         (1) 
Where; % cytotoxicity = [(O. D. of control cells – O. D. of 
cells treated with the test formulation)/O. D. of control 
cells]*100.  
The concentration that resulted in >75% viability was 
selected for subsequent cytokine estimation.  
2.9. Determination of Cytokines (TNF-α and IL-1β) and 
Chemokine (MIP-1α) Using ELISA 
The in-vitro activity of the Biofield Treated and untreated 
test formulations were estimated on the mice splenocytes for 
the production of TNF-α, MIP-1α, and IL-1β using enzyme-
linked immunosorbent assay (ELISA). The ELISA plates 
were coated with an antibody in a coating buffer at the 
recommended concentration and kept overnight at 4ºC. After 
washing with PBS-T (PBS with 0.05% Tween 20), the plates 
were blocked with assay diluent for at least 2 hours at room 
temperature. A total of 100 µL culture supernatant from 
different experimental samples and standards were incubated 
overnight at 4ºC and, after three washes, biotinylated anti-
mice cytokine (TNF-α, MIP-1α, and IL-1β) antibodies at the 
recommended concentrations were incubated for 1 hour at 
room temperature and the plate was incubated for 45 minutes 
at room temperature with gentle shaking. The plates were 
again washed 3 times and then 100 µL of horseradish per-
oxidase (HRP)–streptavidin conjugate solution was added 
and the plate was incubated for 45 minutes at room 
temperature with gentle shaking. Next, the plate wells were 
washed 3 times as previous and 100 µL of 3,3,5,5'-
tetramethylbenzidine (TMB) one-step substrate reagent was 
added, followed by a 30-minute incubation at room 
temperature in the dark. Further, 50 µL of 0.2 mol/L 
sulphuric acid was added to each well to stop the reaction 
and the plates were read for absorbance at 450 nm using a 
BioTek Reader (SIAFRT/Synergy HT multimode reader). 
Standards were run in parallel to the samples, and the 
concentrations were determined in triplicate for each sample 
[37]. 
2.10. Statistical Analysis 
Data were expressed as mean ± SEM and were subjected 
to one-way analysis of variance (ANOVA) followed by 
Dunnett’s method and Student’s t-test for two groups 
comparison. Statistical significance was considered at 
p≤0.05. 
 
Figure 1. MTT assay in the splenocyte cells after the 48-hours of treatment with different test formulation concentrations in the presence of 0.5 µg/mL LPS. 
The absorbance of the MTT formazan was determined at 540 nm in an ELISA reader. Cell viability was defined as the absorbance ratio (expressed as a 
percentage) of the test formulation treated cells relative to the untreated vehicle control group. 
3. Results 
3.1. MTT Assay on Splenocyte Cells 
The effect of the Biofield Treated and untreated test 
formulations on the proliferation of mice splenocyte cells 
was examined after 48 hours through MTT cell viability 
assay. The effect of the test formulation on the viability of the 
splenocytes is shown in Figure 1. The results showed the % 
cell viability was altered after Biofield Treatment in the 
tested concentration of the test formulation. The untreated, 
LPS, and Con-A group showed 100%, 171.7%, and 201.9% 
cell viability, respectively. The vehicle control group reported 
with 100% and the rapamycin group as 98.9% and 89.9% at 
concentrations 1 and 10 nm, respectively. The increased cell 
viability with respect to vehicle control might be due to 
proliferation in cell culture. Con-A and rapamycin showed 
immunostimulatory and immunosuppressive action, 
respectively, as used as positive control in the experiment. 
Concentration range of 0.00001053 to 10.53 µg/mL was 
selected for comparison of cell viability after adding the 
Biofield Treated and untreated test formulations to the 
splenocyte cells. The test formulation was found safe at 
concentration up to 1.053 µg/mL with percentage viability 
range from 76.7% and 109.2%. The cell viability was greatly 
decreased at the concentration of 10.53 µg/mL in both the 
Biofield Treated (20.9%) and the untreated formulations 
(33.9%), so this concentration was not selected for the 
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estimation of cytokines. However, at three tested 
concentrations the Biofield Treated test formulation showed 
increased cell viability, i.e. at 0.0001053, 0.01053, and 1.053 
µg/mL, while the rest of the three concentrations showed 
decreased cell viability i.e. at 0.00001053, 0.001053, and 
0.1053 µg/mL with respect to the vehicle control group. The 
percentage of increased cell viability in the Biofield Treated 
test formulation was 1.00%, 2.89%, and 0.29% at 0.0001053, 
0.001053, and 1.053 µg/mL respectively as compared with 
the untreated test formulation. Similarly, the concentrations 
0.0001053, 0.01053, and 1.053 µg/mL showed increased cell 
viability as 0.9%, 9.2%, and 5.5%, respectively as compared 
with the vehicle control group. The percentage of decreased 
cell viability reported at 0.00001053, 0.01053, and 0.1053 
µg/mL was 22.36%, 2.58%, and 14.54%, respectively in 
comparison to the untreated test formulation. Overall, the 
results showed that the cell viability was significantly altered 
after the Biofield Energy Treatment.  
3.2. Effect of the Test Formulation on the Expression of 
Pro-Inflammatory Cytokines (TNF-α and IL-1β) and 
Chemokine (MIP-1α) in the Splenocyte Cells 
The effect of the Biofield Treated herbomineral 
formulation was observed on pro-inflammatory cytokines 
TNF-α, MIP-1α, and IL-1β. All play a major role in 
inflammation, immune modulation, and lymphocyte 
activation, so it might be expected that the herbomineral 
formulations can modulate the expression and activation of 
cytokines. Therefore, the expression of TNF-α, MIP-1α and 
IL-1β at six concentrations was examined in the spleen cells. 
The effect of the test formulation on pro-inflammatory 
cytokines was estimated by incubating the formulation with 
various concentrations of the treated and untreated test 
formulations for 48 hours using ELISA assay. 
3.2.1. Assessment of TNF-α Expression 
The effect of the Biofield Treated and untreated test 
formulations on TNF-α secretions in splenocyte cells are 
represented in Figure 2. Results suggest that both the 
untreated and Biofield Treated groups demonstrated 
suppression of TNF-α secretions at different tested 
concentrations i.e. at 0.00001053 to 1.053 µg/mL. The 
negative control (untreated cells), LPS, Con-A, and vehicle 
control group showed TNF-α values as 87.60, 504.65, 
271.32, and 501.55 pg/mL, respectively. However, the 
untreated test formulation demonstrated suppression of 
TNF-α from LPS stimulated levels at five tested 
formulation concentrations out of six i.e. at 0.0001053, 
0.001053, 0.01053, 0.1053, and 1.053 µg/mL by 12.51%, 
7.50%, 6.49%, 5.80%, and 16.46%, respectively as 
compared with the vehicle control. The maximum 
decreased value of TNF-α of the untreated test formulation 
was reported at 1.053 µg/mL i.e. 418.99 pg/mL. At three 
tested concentrations, the Biofield Treated test formulation 
showed an inhibition of TNF-α i.e. at 0.01053, 0.1053, and 
1.053 µg/mL by 1.77%, 1.93%, and 3.55%, respectively as 
compared to the vehicle control group. The maximum 
inhibition of TNF-α in the Biofield Energy Treated test 
formulation was reported (483.72 pg/mL) at the test 
formulation concentration 1.053 µg/mL as compared to the 
vehicle control. On the other hand, the Biofield Energy 
Treated test formulation demonstrated an increase in TNF-α 
at three tested formulation concentrations i.e. 0.00001053, 
0.0001053, and 0.001053 µg/mL by 7.26%, 8.50%, and 
8.50%, respectively as compared to the vehicle control 
group. Overall, it can be suggested that the test formulation 
has immunosuppressive effects by inhibiting the 
concentration of TNF-α as compared with the vehicle 
control, while the Biofield Energy Treatment has increased 
the concentration of TNF-α in all the concentrations as 
compared with the untreated formulation. The Biofield 
Energy Treatment showed a significant effect on altering 
the level of TNF-α as compared to the untreated test 
formulation.  
 
Figure 2. Concentration-dependent effect on TNF-α by the Biofield Treated and untreated test formulations. For each concentration treatment, the level of 
TNF-α release was measured after receiving 48-hours of treatment. All values are represented (in pg/mL) as mean ± SEM. 
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3.2.2. Estimation of MIP-1α Expression 
The effect of the Biofield Energy Treated and untreated 
test formulations on MIP-1α secretion is shown in Figure 3. 
The figure demonstrates that the Biofield Treated and 
untreated test formulations inhibit the expression of MIP-1α 
as compared with the vehicle control group. However, the 
comparative effect of the Biofield Energy Treated and 
untreated test formulations on MIP-1α secretion in 
splenocyte cells showed significant alterations at all the 
tested concentrations. The untreated cells, LPS, Con-A, and 
vehicle control group showed values of MIP-1α as 42.8 ± 14, 
598.6 ± 11.2, 285.5 ± 10.3, and 768.0 ± 10.2 pg/mL, 
respectively. The untreated test formulation showed 
significant inhibition of MIP-1α secretion at all the tested 
concentrations i.e. at 0.00001053, 0.0001053, 0.001053, 
0.01053, 0.1053, and 1.053 µg/mL by 24.27%, 41.30%, 
45.72%, 18.11%, 19.18%, and 36.15%, respectively as 
compared to the vehicle control group. The Biofield Energy 
Treatment further enhanced the immunosuppressive property 
of the test formulation by 18.47%. The enhanced activity of 
MIP-1α expression was reported at concentration 0.01053 
µg/mL i.e. 512.74 ± 1.9 pg/mL in the Biofield Treated test 
formulation and 628.94 ± 13.0 pg/mL in the untreated 
formulation. It showed significant decreased level of MIP-1α 
by 18.47% (p≤0.001) as compared to the untreated 
formulation. The rest of the other Biofield Treated test 
formulation concentrations showed an increased level of 
MIP-1α as compared with the untreated test formulation. 
However, the Biofield Energy Treated test formulation group 
reported an inhibition of MIP-1α secretion at 0.00001053, 
0.0001053, 0.001053, 0.01053, 0.1053, and 1.053 µg/mL by 
25.41%, 25.71%, 35.55%, 33.24%, 19.18%, and 27.78%, 
respectively as compared with the vehicle control group.  
 
Figure 3. Concentration-dependent inhibition of LPS mediated production of MIP-1α by the Biofield Treated and untreated test formulations. For each 
concentration treatment, the level of MIP-1α release was measured after receiving 48-hours of treatment. The values are represented in pg/mL as mean ± SEM 
(***p≤0.001, **p≤0.01, and *p≤0.05, as compared with the untreated test formulation). 
3.2.3. Estimation of IL-1β Expression 
The effect of the Biofield Treated and untreated test 
formulations on IL-1β expression is shown in Figure 4. The 
figure demonstrates the inhibition of IL-1β after treatment 
with the Biofield Energy Treated and untreated test 
formulations as compared with the vehicle control group. 
However, the comparative effect of the treated and untreated 
test formulations on IL-1β secretion in splenocyte cells 
showed significant inhibition at 5 tested concentrations out of 
6. The untreated cells, LPS, Con-A, and vehicle control 
group showed values of IL-1β as 7.67 ± 1.9, 78.86 ± 5.8, 
19.48 ± 4.5, and 54.90 ± 3.4 pg/mL, respectively. The 
untreated test formulation showed a significant inhibition of 
IL-1β secretion at all the tested concentrations i.e. at 
0.00001053, 0.0001053, 0.001053, 0.01053, 0.1053, and 
1.053 µg/mL by 77.21%, 40.13%, 31.73%, 36.62%, 43.24%, 
and 42.78%, respectively as compared with the vehicle 
control group. The Biofield Treatment showed further 
significant improvement in the immunosuppressive property 
of the test formulation at all the concentrations, except at 
0.00001053 µg/mL, as compared to the untreated 
formulation. The significant inhibition of IL-1β secretion 
after the Biofield Treatment was reported at the 
concentrations viz. 0.001053, 0.01053, 0.1053, and 1.053 
µg/mL by 72.02%, 50.16%, 30.68%, and 22.11%, 
respectively as compared with the untreated formulation. The 
maximum IL-1β secretion inhibition was reported in the 
Biofield Treated test formulation at 0.001053 µg/mL. While 
60.17 ± 7.7 was reported in the untreated test formulation, 
the Biofield Treated sample reported 16.84 ± 1.8 pg/mL 
(p≤0.01). However, the Biofield Treated group reported an 
inhibition of IL-1β secretion at 0.00001053, 0.0001053, 
0.001053, 0.01053, 0.1053, and 1.053 µg/mL by 35.36%, 
43.24%, 80.89%, 68.41%, 60.65%, and 55.42%, respectively 
as compared with the vehicle control group. 




Figure 4. Concentration-dependent inhibition of LPS mediated production of IL-1β by the test formulations. For each concentration treatment, the level of IL-
1β release was measured in cell supernatant after receiving 48-hours of treatment. All values are represented in pg/mL as mean ± SEM (**p≤0.01, as 
compared with the untreated test formulation). 
4. Discussion 
Traditional, alternative and complementary medicines and 
therapies play a major role worldwide with respect to the 
current human wellness and traditional healthcare sectors, 
including overall healthcare management, longevity, anti-
aging and quality of life. However, more attention is required 
to understand the use of alternative energy medicine and its 
utilization in current healthcare systems. The scope of 
traditional medicine has only been improved in developing 
countries [38], but the use of Biofield Energy as a 
Complementary and Alternative Medicine (CAM) approach 
still requires implementation in the practice by many 
scientific research. The herbal medicine industry is 
increasing worldwide more than 10% annually, and it may 
reach up to $5 trillion by the year 2050 [39]. Many 
herbomineral products have shown significant effect in 
curing many diseases with minimal adverse effects. One 
widely used example of an herbomineral formulation is the 
Naga bhasma in the Indian system of medicines, which is 
used for various disorders such as diabetes, indigestion, 
inflammation of the intestine, osteomalacia, blood disorders, 
infertility, regenerate germinal epithelium of the testes, as a 
potent revitalizer, and many more uses within our bodies 
[40]. The Trivedi Effect®-Biofield Energy Healing (TEBEH) 
is a new proprietary method that can be used to enhance the 
impact of herbomineral formulations, which can be further 
used to modulate the immune function with long-term 
effectiveness and minimal toxicity at a lower cost, which 
might improve overall health and quality of life.  
The individual ingredients of the herbomineral 
formulation, including ashwagandha and zinc chloride, have 
already been reported in many scientific reports to modulate 
the inflammatory response using cytokines estimation [4-7]. 
Lymphocyte proliferation and the activation of NK cells are 
cytokine dependent [41], and its up and down regulation 
could affect the course of immune response and the whole 
network of immune regulation. The individual components, 
such as ashwagandha, have been reported to inhibit the NF-
κB and AP-1 transcription factors in human peripheral blood 
and synovial fluid mononuclear cells [42]. With respect to the 
minerals present in the formulation, the deficiency of zinc 
directly influenced the cytokines generation such as IL-2, IL-
6, IL-1β, and TNF-α, and influenced its generation in a 
concentration depended manner. It was reported that zinc 
also alters the cytokines generation by inhibiting the 
activation of NF-κB [43]. 
Magnesium also plays an important role in the activation 
of NF-κB, and affects the generation of cytokines, and would 
be effective in the risk situations associated with 
inflammation or its related diseases pathogenesis [44]. 
However, selenium from the diet mostly incorporates into 
selenoproteins, and plays an important role in inflammation 
and for initiating immunity. Selenium influences different 
leukocytes effector functions such as cytokines secretion, 
migration, adherence, and phagocytosis. It plays an important 
role in cytokine production using calcium flux and oxidative 
pathway [45-47].  
Study results suggest that the Biofield Treated test 
formulation showed an anti-inflammatory effect and 
suppressed the level of tested cytokines as compared with the 
vehicle control group. However, the Biofield Energy Treated 
formulation further potentiated the effect as compared with 
the untreated test formulation, which may better prevent the 
progression of acute or chronic infection, because 
inflammation is regarded as the first response that releases 
cytokines. Thymus and spleen cell proliferation are 
considered as vital parameters to maintain immune 
homeostasis [48]. Inhibition of cytokines such as TNF-α, IL-
1, and IL-6, and eicosanoid such as PGE2 from any 
formulation can be considered to have anti-inflammatory 
properties, and the Biofield Energy Treated test formulation 
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can be better utilized as an anti-inflammatory agent in 
comparison to the untreated test formulation.  
Cells viability assay (MTT) suggest that the Biofield 
Treated and untreated test formulations’ concentration was 
found safe with respect to the in vitro viability of splenocytes 
until concentration 1.053 µg/mL, while the viability 
percentage was increased after the Biofield Energy 
Treatment. The MTT assay evaluates the metabolic activity 
by measuring the activity of succinate dehydrogenase, a 
mitochondrial enzyme. This test is widely used in the in vitro 
evaluation of the cell toxicity of any test drug. MTT assay is 
regarded as more rapid, less costly, less time consuming, and 
as a non-radioactive method to show the cell proliferation 
results on the basis of cell growth and metabolic activity 
[49]. Further, the level of TNF-α was inhibited at three tested 
higher concentrations i.e. 0.01053, 0.1053, and 1.053 µg/mL 
by 1.77%, 1.93%, and 3.55%, respectively by the Biofield 
Treated test formulation. Thus, it can be concluded that the 
Biofield Energy Treatment potentiated the inhibition and 
showed immunosuppressive activity at higher concentrations. 
TNF-α plays a major role in immune disorders, and is the 
controlling factor for many diseases [50]. However, the level 
of MIP-1α was inhibited at all of the Biofield Treated test 
formulation concentrations with respect to the vehicle 
control, while showing significant inhibition at 0.01053 
µg/mL i.e. 18.74% with respect to the untreated test 
formulation. Reduction of MIP-1α levels might be useful in 
decreasing the inflammatory responses [51].  
Similarly, the expression of IL-1β was further significantly 
potentiated after the Biofield Treatment on the test 
formulation at all concentrations, except lower concentration 
values i.e. 0.00001053 µg/mL. The percentage of inhibition 
ranged from 22.11% to 72.02% in the Biofield Treated test 
formulation as compared with the untreated test formulation. 
Immunological and inflammatory functions of IL-1β in 
controlling the immune response during infections are well 
defined [52, 53]. Overall, the inhibitory effect might be the 
result of specific inhibition of NF-κB, a transcription factor 
involved in the activation of many inflammatory mediator 
genes. The results also reflect that the Biofield Treated test 
formulation showed immunosuppressive activity in LPS 
stimulated splenocyte cells on pro-inflammatory cytokines 
(TNF-α, MIP-1α, and IL-1β) secretion, which can be 
concluded that the Biofield Treated test formulation has the 
potential to act on the innate immune system. LPS was used 
in the study to induce the immune system to depict the 
disease state. The effect was significant with respect to all 
cytokines as they are deeply associated with inflammatory 
disorders (such as TNF-α and IL-1β for chronic 
inflammation). In the case of many autoimmune disorders, 
such as rheumatoid arthritis, steroids (prednisolone and 
dexamethasone) are preferred to suppress the cytokines 
production. However, this study suggests that a Biofield 
Treated formulation would be a better choice of treatment 
and has no toxicity. Besides, it can also be preferred for the 
inhibition of T and B lymphocytes, which could help in 
immune-mediated disorders such as autoimmune disorders, 
stress, and asthma [54]. 
Biofield Energy Healing has been succesfully reported in 
the case of cancer cell lines with respect to the inhibition of 
cytokine expression such as IL-1α and IL-1β levels [55]. 
Complementary and alternative medicine (energy therapy) 
has been reported with various benefits as compared with the 
conventional treatment approach. The National Center for 
Complementary and Integrative Health (NCCIH) under the 
National Institutes of Health (NIH) have recognized the 
siginificant outcomes of energy medicine [56].  
5. Conclusions 
The in vitro results of the Biofield Energy Treated and 
untreated test formulations showed significant modulatory 
effects on splenocyte cells isolated from mice with respect to 
the suppression of tested cytokines. All the tested cytokines 
(TNF-α, MIP-1α, and IL-1β) were reported with 
immunosuppressive activity with respect to the vehicle 
control group, while the Biofield Energy Treatment further 
potentiated the immunomodulation as compared with the 
untreated test formulation. The results of in vitro splenocyte 
cells’ viability assay suggest that most of the tested 
concentration of the Biofield Treated and untreated test 
formulations showed improved cell viability, except at the 
higher concentration of 10.53 µg/mL. The cell viability after 
the Biofield Energy Treatment significantly improved with 
the Biofield Treated test formulation at concentrations 
0.0001053, 0.001053, and 1.053 µg/mL with respect to the 
untreated test formulation. The results of the cytokines 
estimation revealed that the Biofield Treated group 
suppressed the TNF-α, MIP-1α and IL-1β. TNF-α levels, 
which were significantly inhibited at three tested 
concentrations of 0.01053, 0.1053, and 1.053 µg/mL by 
1.77%, 1.93%, and 3.55%, respectively in the Biofield 
Treated test formulation as compared with the untreated test 
formulation. In the case of MIP-1α, both the untreated and 
Biofield Treated test formulation showed significant 
suppression, while the Biofield Energy Treatment enhanced 
the immunosuppressive activity at the concentration 0.01053 
µg/mL by 18.47% (p≤0.001) as compared to the untreated 
formulation. The values of MIP-1α reported in the case of the 
untreated formulation was 628.94 ± 13.0 pg/mL, while it was 
decreased to 512.74 ± 1.9 pg/mL in the Biofield Energy 
Treated test formulation. Similarly, significant inhibition 
(p≤0.001) of IL-1β secretion was reported in the Biofield 
Treated test formulation at concentration 0.001053, 0.01053, 
0.1053, and 1.053 µg/mL by 72.02%, 50.16%, 30.68%, and 
22.11%, respectively as compared with the untreated 
formulation.  
On the basis of the above estimation, it can be concluded 
that after receiving the Biofield Energy Healing Treatment 
(The Trivedi Effect®), administered remotely by the seven 
Biofield Energy Healers to the new herbomineral formulation 
significantly inhibited the activity of pro-inflammatory 
cytokines that might prevent the over-activation of the 
immune system. The Biofield Energy Treated test 
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formulation can be a better complementary and alternative 
medicine to prevent the immune-mediated tissue damage in 
cases of organ transplants (for example kidney transplants, 
liver transplants and heart transplants), various autoimmune 
disorders such as Lupus, Addison Disease, Celiac Disease 
(gluten-sensitive enteropathy), Dermatomyositis, Graves’ 
Disease, Hashimoto Thyroiditis, Multiple Sclerosis (MS), 
Myasthenia Gravis, Pernicious Anemia, Aplastic Anemia, 
Reactive Arthritis, Rheumatoid Arthritis, Sjogren Syndrome, 
Systemic Lupus Erythematosus, Type 1 Diabetes, Alopecia 
Areata, Crohn’s Disease, Fibromyalgia, Vitiligo, Psoriasis, 
Scleroderma, Chronic Fatigue Syndrome and Vasculitis, as 
well as inflammatory disorders such as Asthma, Ulcerative 
Colitis, Alzheimer’s Disease, Atherosclerosis, Dermatitis, 
Diverticulitis, Hepatitis, Irritable Bowel Syndrome, 
Parkinson’s Disease and stress etc. with a safe therapeutic 
index to improve overall health and quality of life. Further, 
the Biofield Energy Healing Treated test formulation can also 
be used in the prevention of immune-mediated tissue damage 
in cases of organ transplants (for example heart transplants, 
kidney transplants and liver transplants), for anti-aging, stress 
prevention and management, and in the improvement of 
overall health and quality of life. 
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